Post-earnings recap
Reported
Wed, Nov 2, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report shows that 10X Genomics exceeded expectations on EPS, which is a positive sign for the company. However, the stock fell by 4.61% following the announcement, likely due to the lack of revenue data and guidance. Investors may be concerned about the company's future performance without clear direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.37 | N/A | +18.32% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a cautious optimism about future opportunities while recognizing current market challenges.
Management highlighted ongoing investments in innovation and product development.
They acknowledged challenges in the market but expressed confidence in long-term growth.